NovoCure
NVCR
166 hedge funds and large institutions have $1.94B invested in NovoCure in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 62 reducing their positions, and 39 closing their positions.
591% more call options, than puts
Call options by funds: $31.4M | Put options by funds: $4.54M
2.58% more ownership
Funds ownership: 59.81% → 62.39% (+2.6%)
6% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 62
6% less funds holding
Funds holding: 176 → 166 (-10)
23% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 39
33% less capital invested
Capital invested by funds: $2.9B → $1.94B (-$955M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
Darsana Capital Partners
New York
|
+$48.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.3M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$35.5M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$19.8M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$36.8M |
| 2 |
Two Sigma Investments
New York
|
-$22.3M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$11.8M |
| 4 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
-$8.52M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$8.16M |
NVCR Hedge Fund Activity: Q4 2018 in Review
166 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2018, worth a combined $1.94B — down 33% from $2.9B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of NVCR and 30 opened new positions — a net loss of 9 holders — while 62 trimmed existing stakes and 58 added.
The largest buyer was Darsana Capital Partners, adding an estimated $48.5M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $36.8M sold.
- 166 institutional investors held NovoCure (NVCR) as of Q4 2018, down from 176 in Q3 2018.
- Funds reported $1.94B of NovoCure stock for Q4 2018, down 33% quarter-over-quarter.
- 30 funds opened new NovoCure positions in Q4 2018 and 39 closed out, a net change of -9 holders.
- The largest NovoCure buyer in Q4 2018 was Darsana Capital Partners, an estimated $48.5M added.
- The largest NovoCure seller in Q4 2018 was Loomis, Sayles & Company, an estimated $36.8M sold.
Based on aggregated 13F filings for Q4 2018.